These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 31594064

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ, Hu LY, Geng QR, Chen J, Lu ZH, Rao HL, Liu Q, Jiang WQ, Huang HQ, Lin TY, Xia ZJ.
    Chin J Cancer; 2016 Sep 13; 35(1):87. PubMed ID: 27624700
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].
    Guo J, Zhu YP, Gao J, Li Q, Jia CS, Zhou CY, Guo X.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb 13; 24(1):72-9. PubMed ID: 26913397
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
    Wang C, Li W, Liu C, He H, Bai O.
    Blood Cells Mol Dis; 2016 Mar 13; 57():42-9. PubMed ID: 26852654
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Long-term efficacy and prognostic factors of Beijing Children's Hospital-2009-lymphoblastic lymphoma in the treatment of T-lymphoblastic lymphoma in children and adolescents].
    Jin L, Yang J, Duan YL, Huang S, Zhang M, Zhou CJ, Zhang NN, Zhang YH.
    Zhonghua Yi Xue Za Zhi; 2024 Jul 30; 104(29):2759-2766. PubMed ID: 39075996
    [Abstract] [Full Text] [Related]

  • 11. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
    Teoh CS, Lee SY, Chiang SK, Chew TK, Goh AS.
    Asian Pac J Cancer Prev; 2018 May 26; 19(5):1229-1236. PubMed ID: 29801406
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
    Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, Belch A, Walewski J, Zinzani PL, Mingrone W, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Corrado C, Scheliga A, Loeffler M, Kuhnt E, MabThera International Trial (MInT) Group.
    Lancet Oncol; 2008 May 26; 9(5):435-44. PubMed ID: 18400558
    [Abstract] [Full Text] [Related]

  • 14. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
    Yao WK, Wang YP, Peng F, Zheng Y, Zou YB, Gao JN, Liu XL.
    Zhonghua Bing Li Xue Za Zhi; 2012 Dec 26; 41(12):818-22. PubMed ID: 23324230
    [Abstract] [Full Text] [Related]

  • 15. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, Hans CP, Greiner TC, Bierman PJ, Bociek RG, Armitage JO, Chan WC, Vose JM.
    J Clin Oncol; 2008 Oct 01; 26(28):4587-94. PubMed ID: 18662967
    [Abstract] [Full Text] [Related]

  • 16. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
    Mondello P, Steiner N, Willenbacher W, Ferrero S, Ghione P, Marabese A, Pitini V, Cuzzocrea S, Mian M.
    Oncologist; 2016 Sep 01; 21(9):1107-12. PubMed ID: 27382029
    [Abstract] [Full Text] [Related]

  • 17. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP, Mihaljevic B, Jakovic L, Martinovic VC, Fekete MD, Andjelic B, Antic D, Bogdanovic A, Boricic N, Terzic T, Jelicic J, Milenkovic S.
    J BUON; 2015 Sep 01; 20(3):820-8. PubMed ID: 26214636
    [Abstract] [Full Text] [Related]

  • 18. [Retrospective analysis of the clinical features and prognostic factors of 370 patients with advanced-stage diffuse large B-cell lymphoma].
    Han Y, Qin Y, He XH, Yang JL, Liu P, Zhang CG, Zhou LQ, Zhou SY, Gui L, Song YW, Sun Y, Shi YK.
    Zhonghua Zhong Liu Za Zhi; 2018 Jun 23; 40(6):456-461. PubMed ID: 29936773
    [Abstract] [Full Text] [Related]

  • 19. [Clinical analysis of 60 children with anaplastic large cell lymphoma in a single center].
    Wang M, Mi Q, Yuan Q, Han YL, Wang JM, Luo CY, Pan C, Tang JY, Gao YJ.
    Zhonghua Er Ke Za Zhi; 2021 Oct 02; 59(10):824-829. PubMed ID: 34587677
    [Abstract] [Full Text] [Related]

  • 20. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
    Mao L, Wang X, Wang CY, Xia B, Ning QY, Yang HL, Yu Y, Zhang YZ.
    Zhonghua Yi Xue Za Zhi; 2019 Jun 25; 99(24):1853-1858. PubMed ID: 31269579
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.